-
Product Insights
Human SARS Coronavirus 2 Nucleoprotein – Drugs In Development, 2023
Global Markets Direct’s Human SARS Coronavirus 2 Nucleoprotein provides in depth analysis on Human SARS Coronavirus 2 Nucleoprotein targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human...
-
Product Insights
Human SARS Coronavirus 2 RNA Dependent RNA Polymerase – Drugs In Development, 2023
Global Markets Direct’s Human SARS Coronavirus 2 RNA Dependent RNA Polymerase provides in depth analysis on Human SARS Coronavirus 2 RNA Dependent RNA Polymerase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy 2 For Oncology And Coronavirus Disease 2019 (COVID-19) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy 2 For Oncology And Coronavirus Disease 2019 (COVID-19) in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy 2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olokizumab in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olokizumab in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olokizumab in Rheumatoid Arthritis Drug Details: Olokizumab (Artlegia) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leronlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leronlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leronlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Leronlimab (PRO-140)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leronlimab in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leronlimab in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leronlimab in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Leronlimab (PRO-140)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IRL-201104 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IRL-201104 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IRL-201104 in Asthma Drug Details: IRL-201104 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IRL-201104 in Food Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IRL-201104 in Food Allergy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IRL-201104 in Food Allergy Drug Details: IRL-201104 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-38 in Lyme Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-38 in Lyme Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-38 in Lyme Disease Drug Details: CT-38 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIT-001 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIT-001 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIT-001 in Asthma Drug Details: MIT-001 is under development for the treatment of...